A comparative study of efficacy, safety and tolerability of sitagliptin versus glimeperide in patients of type-2 diabetes mellitus inadequately controlled with metformin alone.

Dr J. L. Marko; Dr Rakesh Sonawane; Dr Ashutosh Chourishi

Volume : VII, Issue : II, February - 2018

A comparative study of efficacy, safety and tolerability of sitagliptin versus glimeperide in patients of type-2 diabetes mellitus inadequately controlled with metformin alone.

Dr J. L. Marko, Dr Rakesh Sonawane, Dr Ashutosh Chourishi

Abstract :

The present study was designed to study the efficacy, safety and tolerability of sitagliptin in comparison with glimepiride in treatment of type 2 diabetes mellitus inadequately controlled with metformin alone. A total of 70 patients were included in the study out of which 35 patients were grouped in metformin plus glimepiride group and the rest 35 were grouped in the metformin plus sitagliptin group. This study was designed to evaluate the efficacy, safety and tolerability of sitagliptin in comparison with glimepiride as an add–on drug to metformin in type 2 diabetes mellitus as an objective. Both treatment groups were compared for the mean reduction in HbA1c from baseline to 18th week defined as a primary end–point. While mean reduction in fasting blood sugar and post prandial blood sugar from baseline to 18^th week defined as secondary end point. Mean dose for the glimepiride group was 2.1 mg while 100 mg in sitagliptin group. Both treatments were successful in decreasing and improving HbA1c level over the course of the study. Mean HBA1C level at baseline in metformin plus glimepiride group was 8.31%. This was comparable (p=0.06) to metformin plus sitagliptin group in which the HbA1c at baseline was 8.56%. There was significant decrease in the HbA1c level in both the groups from baseline at the end of 18 week study period.